HK Stock Market Move | Inbf shares rise again, Shanghai launches acquisition of second-hand houses for rental housing, Pudong, Jing'an and Xuhui lead the way.
Inner room stocks rose again. As of press time, Greentown China (03900) rose by 6.45% to 11.22 Hong Kong dollars; Sunac China (01918) rose by 6.19% to 1.2 Hong Kong dollars; China Jinmao (00817) rose by 6.71% to 1.75 Hong Kong dollars; and Shimao Development (01030) rose by 4.44% to 2.59 Hong Kong dollars.
Inner-city property stocks rose again, as of press time, GREENTOWN CHINA (03900) rose 6.45% to 11.22 Hong Kong dollars; SUNAC (01918) rose 6.19% to 1.2 Hong Kong dollars; CHINA JINMAO (00817) rose 6.71% to 1.75 Hong Kong dollars; SEAZEN (01030) rose 4.44% to 2.59 Hong Kong dollars.
On the news front, on February 2, China Construction Bank Corporation supported the first batch of Shanghai's acquisition of second-hand housing for affordable rental housing projects, marking the substantial start of the work in Shanghai to acquire second-hand housing for affordable rental housing. At the signing ceremony, the relevant branches of China Construction Bank Corporation's Shanghai branch signed cooperation agreements with the public housing companies in the first pilot areas of Pudong New Area, Jing'an District, and Xuhui District, providing financial support for the acquisition work.
Goldman Sachs released a research report stating that recent reports confirmed that several real estate developers have confirmed that central regulatory agencies no longer require monthly submission of "three red line" indicator data. Communication with several developers showed that these monthly reports had actually been suspended a year ago. The rise in the inner-city property sector due to the above news reflects that the recovery of housing demand is still a long way off, and liquidity injection remains the core driver of industry stock price recovery in the short term.
Related Articles
.png)
HK Stock Market Move | SF INTRA-CITY(09699) rose more than 4%, with an expected year-on-year profit growth of no less than 80% by 2025.

HK Stock Market Move | HENLIUS (02696) rose nearly 5% in early trading. The HLX22 head-to-head K drug for gastric cancer phase III clinical trial conducted by American researchers will be successfully held.

HK Stock Market Move | STANCHART (02888) rose more than 4% during trading, Standard Chartered's high-end individual client base in the Greater Bay Area saw strong growth in new clients. In the future, the company will increase market expansion in China.
HK Stock Market Move | SF INTRA-CITY(09699) rose more than 4%, with an expected year-on-year profit growth of no less than 80% by 2025.
.png)
HK Stock Market Move | HENLIUS (02696) rose nearly 5% in early trading. The HLX22 head-to-head K drug for gastric cancer phase III clinical trial conducted by American researchers will be successfully held.

HK Stock Market Move | STANCHART (02888) rose more than 4% during trading, Standard Chartered's high-end individual client base in the Greater Bay Area saw strong growth in new clients. In the future, the company will increase market expansion in China.

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


